Hydroxychloroquine Associated With Lower COVID-19 Mortality: Study

[Elderberry]

The Epoch Times By Zachary Stieber 11/3/2023

The French study included 30,202 patients.

People who received hydroxychloroquine were less likely to die than those who did not, according to a new study.

Just 0.8 percent of patients at a facility in France who received hydroxychloroquine (HCQ) and an antibiotic died, compared to 4.8 percent of patients who did not receive the drug combination, French researchers reported on Nov. 1.

"This study represents the largest single-center study evaluating HCQ-AZ in the treatment of COVID-19. Similarly, to other large observational studies, it concludes that HCQ would have saved lives," Dr. Didier Raoult, with Aix-Marseille Universite in Marseille, and his co-authors wrote.
The paper was published in the journal New Microbes and New Infections. It was released as a preprint earlier this year, but withdrawn because authors said they have changed their "analytic strategies."

Researchers examined records from 30,423 patients with COVID-19 who were treated at another institution in Marseille, IHU Méditerranée Infection. They included all adults who tested positive for COVID-19 and who were treated in the hospital as an inpatient or an outpatient between March 2, 2020, and Dec. 31, 2021.

The study set ended up with 30,202 patients because treatment information was not available for the 221 others.

Most of the patients received off-label prescriptions of hydroxychloroquine and azithromycin (AZ), a common antibiotic.

Of the set, 23,172 patients received the drug combination. The other 7,030 did not.

Among those who received the drugs, 191, or 0.8 percent, died. Among those who did not, 344, or 4.8 percent, passed away.

More: https://www.theepochtimes.com/health/hydroxychloroquine-associated-with-lower-covid-19-mortality-study-5521868

[DB]

Can't make billions using a cheap drug - and costing who knows how many thousands of lives.

[Elderberry]

Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients

Science Direct Volume 55, October 2023, 101188

Abstract

Background

Many studies have evaluated the use of hydroxychloroquine in COVID-19. Most retrospective observational studies demonstrate a benefit of using HCQ on mortality, but not most randomized clinical trials.

Methods

We analyzed raw data collected from a cohort of 30,423 patients with COVID-19 cared for at IHU Méditerranée Infection in Marseille France and extracted from the DRYAD open data platform. We performed univariate and multivariable logistic regressions with all-cause mortality within six weeks. Multivariable logistic regressions were adjusted for sex, age group (<50, 50–69, 70–89 and ​> ​89 years), periods (or variants), and type of patient management.
Results

Among 30,202 patients for whom information on treatment was available, 191/23,172 (0.82%) patients treated with HCQ-AZ died, compared to 344/7030 (4.89%) who did not receive treatment with HCQ-AZ. HCQ-AZ therapy was associated with a lower mortality than treatment without HCQ-AZ (odds ratio (OR) 0.16; 95% confidence interval (CI), 0.14–0.19). After adjustment for sex, age, period, and patient management, HCQ-AZ was associated with a significantly lower mortality rate (adjusted OR (aOR) 0.55, 95% CI 0.45–0.68). On a subsample of 21,664 patients with available variant information, results remained robust after adjustment on sex, age, patient management and variant (aOR 0.55; 95% CI 0.44–0.69). On a subsample of 16,063 patients, HCQ-AZ was still associated with a significantly lower mortality rate (aOR 0.47, 95%CI 0.29–0.75) after adjustment for sex, age, period, patient management, vaccination status and comorbidities.

Conclusion

Analysis of this large online database showed that HCQ-AZ was consistently associated with the lowest mortality.

More: https://www.sciencedirect.com/science/article/pii/S2052297523001075

[jmyrlefuller]

Didier Raoult again. And amazingly, Raoult manages to get the exact same results as he did three years ago, yet no independent researcher seems to come anywhere near that much.

[Smokin Joe]

It makes a guy wonder what would have happened if Zinc supplementation had been used as well.

The HCQ was supposed to act as an ionophore to get the Zn++ ions into the cell to disrupt viral replication. The main dietary source for Zinc is red meat, which is only minimally consumed when one is eating "healthy" (fish and chicken or plant proteins), so anyone following that is likely to be deficient in Zinc from the get-go.